Cell and gene therapy using mesenchymal stem cells (MSCs)

Ozawa, Keiya; Sato, Kazuya; Oh, Iekuni; Ozaki, Katsutoshi; Uchibori, Ryosuke; Obara, Yoko; Kikuchi, Yuji; Itō, Takayuki; Okada, Takashi; Urabe, Masashi; Mizukami, Hiroaki; Kume, Akihiro

doi:10.1016/j.jaut.2007.12.008

Cited by 132 publications

(91 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EPCs can augment vascular repair and revascularization [40]. The great plasticity of bone marrow MNCs includes the ability to repair tissues and modulate the immune potential of components of the MSCs and EPCs [41][42][43]. These advantages offer benefits for the development of cellular therapy for preservation of functional beta-cell mass in diabetes, but the exact mechanism remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus

Wang

et al. 2012

Endocr J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus

Wang

et al. 2012

Endocr J

View full text Add to dashboard Cite

“…The history of the management of MAS associated with autoimmune diseases, together with associated HLH syndromes such as those that may accompany malignancy, primary immunodeficiency, and infection, highlight the critical role of the clinical immunologist at the juncture of the traditional specialties of hematology/oncology, allergy/immunology, infectious disease, rheumatology, and the subdivisions of adult and pediatric medicine thereof [82]. The modern management of MAS and other HLH syndromes has made great strides as a result of therapeutic advances over the last 20 years, similar to promising approaches to therapies [83] and etiology [84] in other clinical settings, but the promise of even greater strides looms as the benefits of standardized nomenclature, systematic investigation, and collaborative medicine take root in the soil of team-based science.…”

Section: Discussionmentioning

confidence: 99%

Macrophage Activation Syndrome in Autoimmune Disease

Deane

Selmi

Teuber

et al. 2010

Int Arch Allergy Immunol

112

View full text Add to dashboard Cite

Macrophage activation syndrome (MAS) is a phenomenon characterized by cytopenia, organ dysfunction, and coagulopathy associated with an inappropriate activation of macrophages. Current diagnostic criteria are imprecise, but the syndrome is now recognized as a form of hemophagocytic lymphohistiocytosis that is characteristically associated with autoimmune diatheses. The diagnosis of incipient MAS in patients with autoimmune disease requires a high index of suspicion, as several characteristics of the disorder may be present in the underlying condition or infectious complications associated with the treatment thereof. Proposed treatment regimens include aggressive approaches that require validation in future controlled studies. This review discusses the major aspects of the pathophysiology, diagnosis, and management of MAS with a focus on the association with autoimmune disease.

show abstract

“…The first one is targeting CSC markers or pathways involved in CSCs using monoclonal antibodies as a novel strategy to improve the outcome of cancer therapy (Deonarain et al, 2009). The second one applies stem cells particularly Mesenchymal Stem Cells (MSCs) as promising platform for cell and gene therapy of incurable cancers (Ozawa et al, 2008). The high tropism of MSCs to cancers, as well as their ability to engraft, survive, and proliferate in the tumor without any immunogenicity and toxicity to the host, makes them ideal vehicle for tumor-selective drug delivery.…”

Section: Introductionmentioning

confidence: 99%